Abstract
INTRODUCTION
The three direct oral anticoagulants (DOACs) dabigatran etexilate (Pradaxa V R , Boehringer Ingelheim, Germany), the prodrug of the direct thrombin inhibitor (DTI) dabigatran, and the two direct Factor Xa inhibitors (DXI) rivaroxaban (Xarelto V R , Bayer, Germany) and apixaban (Eliquis V R , Bristol-Myers Squibb, USA) are now widely used in clinical practice. With edoxaban (Savaysa V R , Lixiana V R , Daiichi Sankyo, Japan), a third DXI has recently been licensed.
Besides the 'proof of concept' indication prevention of venous thromboembolism after elective hip or knee replacement surgery, these drugs are approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation as well as for the treatment and secondary prophylaxis of deep vein thrombosis and pulmonary embolism. Rivaroxaban is also approved in Europe for the secondary prevention of atherothrombotic events following acute coronary syndrome [1] .
Vitamin K antagonists (VKA) require individual dosing and monitoring for dosage control due to their indirect modes of action [2] . In contrast, DOACs have pharmacological profiles allowing fixed-dose regimens without routine monitoring [3] [4] [5] [6] . However, as monitoring may be useful in certain situations such as urgent surgery, bleeding or thromboembolism, corresponding assays and calibrators have become available. Managing potential problems such as interruption of the anticoagulant will be a challenge, especially for patients undergoing cardiothoracic surgery [7] . †The first two authors contributed equally to this study.
For patients on VKA, the procedure of bridging is wellestablished and based on guidelines [8] . Nonetheless, recent literature has revealed a degree of uncertainty about the optimal perioperative management, particularly regarding the need for pre-and postoperative use of heparin [9] . Although the summaries of product characteristics of DOACs suggest periinterventional interruption without heparin bridging, proposals to stop the DOAC 5 days before high/medium bleeding risk surgery and to bridge with LMWH or UFH have been made [10, 11] . The aims of our study were first to investigate the effect of all DOACs and heparins on the various specific assays and, additionally, to show the consequences of (double-) spiked samples with DOACs and heparins on the global and specific coagulation assays. Our investigation should elaborate the pitfalls in the case of any concomitant use of heparin and DOAC.
METHODS

Study design
The study was a single-centre, observational trial. Institutional Review Board approval was obtained from the ethics committee of Bad Oeynhausen (Reg.-No. 22/2014). Otherwise, procedures complied with the guidelines from the Institutional Review Board on the blood transfusion service. Written informed consent was obtained from all patients prior to enrolment.
Our study comprises three parts:
1. Plasma of healthy volunteers was spiked with either DOACs (dabigatran, rivaroxaban and apixaban) or heparins (LMWH and UFH). The concentrations used for DOACs were 0, 50, 100, 200, 300, 400 and 500 ng/ml and for heparins 0, 0.1, 0.25, 0.5, 1, 1.5 and 2 IU/ml (Fig. 1) . The resulting 35 samples from one donor were analysed with a diluted thrombin time (dTT)-assay calibrated with dabigatran and an antifactor Xa (aXa)-assay calibrated with rivaroxaban, apixaban, LMWH and UFH. Each analysis was conducted three times. Every time, plasma from a different donor was used. 2. Plasma from healthy volunteers was spiked with no DOAC or with 200 ng/ml of dabigatran, rivaroxaban or apixaban. In a further step, these samples were additionally spiked with LMWH or UFH (0, 0.1, 0.25, 0.5, 1, 1.5, 2 IU/ml). Besides measurement of the corresponding DOAC with mass spectrometry and the corresponding heparin, all samples were analysed for PT and aPTT (Fig. 2 ). 3. Plasma from patients under drug administration (>14 days) of dabigatran, rivaroxaban or apixaban was collected at different times after drug intake (Fig. 3) . In a further step, these samples were additionally spiked with LMWH or UFH (0, 0.25, 0.5, 1, 2 IU/ml). The corresponding DOAC was measured with mass spectrometry and with either the dTT-assay for dabigatran or the aXa-assay for rivaroxaban or apixaban.
Anticoagulants
Preparations of solutions were described in detail in Eller et al. [12] . In brief, stock solutions of dabigatran, rivaroxaban and apixaban [all: ALSACHIM (Illkrich, France)] were prepared using 50% methanol for dabigatran and 10% dimethyl sulfoxide (DMSO) for rivaroxaban and apixaban. Further dilutions were performed using distilled water. The heparins [LMWH: Enoxaparin (Aventis) and UFH: Heparin Natrium (ratiopharm)] were diluted using 0.9% NaCl to obtain suitable concentrations. 
GENERAL ADULT CARDIAC
Assays
The measurements were performed with an ACL TOP 700 system (Instrumentation Laboratory, Germany). All laboratory tests were performed according to the usual procedures and standards. Dabigatran plasma concentrations were determined using HEMOCLOT V R DTI (CoaChrom Diagnostica, Austria). The anti-Xa activity of samples containing rivaroxaban, apixaban, LMWH or UFH was measured with the COAMATIC V R Heparin (Chromogenix, USA) using the corresponding calibration curves.
For the coagulation assays, the PT reagent RecombiPlasTin 2G and the aPTT reagent SynthASil reagent were used (Instrumentation Laboratory, Germany).
Mass spectrometry
Quantitative measurements of apixaban, dabigatran and rivaroxaban in plasma were performed following a previously described method using ultraperformance liquid chromatography and electrospray ionization-tandem mass spectrometry [13] . 
Statistical analysis
The statistical analysis was performed using the statistical software package R version (3.2.0) (www.r-project.org). The effect of DOAC treatment on heparin measurement was analysed by linear regression using the standard 'lm' function in R. The model included heparin concentration (UFH and LMWH) as a quantitative variable, DOAC (basic concentration) as a categorical factor and the interaction term between heparin and DOAC concentration.
RESULTS
Our study was divided into three parts in order to show 3. The consequences of the use of a DOAC (in patients with an indication for long-term DOAC administration) spiked with one heparin. This was investigated using plasma from the patients with additional ex vivo spiking with either LMWH or UFH (Figs 3 and 6 ).
The effect of DOACs and heparins on the different aXa-and dTT-assays
The concentration-dependent effects of dabigatran, rivaroxaban, apixaban, LMWH and UFH on routinely used monitoring coagulation assays were investigated (Fig. 1 ). All samples were analysed with following assays: dTT, aXa-assay calibrated with rivaroxaban, aXa-assay calibrated with apixaban, aXa-assay calibrated LMWH and aXa-assay calibrated UFH (Fig. 4) . The dTT is used to monitor dabigatran. Anti-Xa-based assays are amidolytic one-stage chromogenic assays based on a synthetic chromogenic substrate and factor Xa inactivation. The anti-Xa active substances were measured with the same reagents using different calibration curves. Every anti-Xa drug delivers a test result for every calibration curve. With the appropriate assay, the measured anticoagulant concentrations were in line with the spiked ones (Fig. 4A , G, M, S and Y). The results were checked for DOACs with mass-spectrometry analysis [13] and show similar results. In addition, the concentrations of each anticoagulant were determined by means of the respective other assays or calibration curves (Fig.  4B-F , H-L, N, R and T-X). The dTT turned out to be a specific assay for DTI as all values were below the cut-off in samples spiked with rivaroxaban, apixaban, LMWH and UFH (Fig. 4K , L, N and O). The only exceptions were the UFH-spiked samples showing marginally prolonged values at high UFH concentrations (Fig. 4O) . Likewise, the aXa-assays did not show any influence from dabigatran. Evaluation of the DXI-spiked samples by the LWMH and UFH calibration curves resulted in apparently supratherapeutic heparin values >1.0 IU/ml for therapeutic DXI concentrations >100 ng/ml (Fig. 4P , Q, U and V). Inversely, heparin-spiked samples evaluated with the DXI calibration curves generally led to apparently sub-therapeutic DXI concentrations <100 ng/ml (Fig. 4D , E, I and J). Furthermore, the rivaroxaban and apixaban results demonstrate that exact DXI determination requires calibration with the respective DXI. Although the rivaroxaban concentrations were overestimated when using the apixaban calibration curve (Fig. 4B) , the apixaban concentrations were underestimated when using the rivaroxaban calibration curve (Fig. 4F ).
Imitation of a bridging situation using doublespiked samples (DOAC and heparin)
Plasma samples containing both a DOAC and a heparin, simulating concomitant use, were examined in the routinely used PT and aPTT as well as in the aXa-assay calibrated with LMWH and UFH, respectively (Fig. 2 ). For this, plasma samples from various healthy volunteers were spiked with 200 ng/ml DXI and DTI, respectively, and with increasing concentrations of either LMWH or UFH. In the aXa-assay, the measured heparin concentrations of the samples containing dabigatran agreed with those of the blank (i.e. without DOAC) samples. In the presence of apixaban and rivaroxaban, significantly higher baseline measurements were observed for calibration curves of UFH (apixaban 1.48 IU/ ml, P < 0.001, 95% confidence interval 1.335-1.629; rivaroxaban 2.08 IU/ml, P < 0.001, 95% confidence interval 1.930-2.224) (Fig.  5A ) and LMWH (apixaban 1.61 IU/ml, P < 0.001, 95% confidence interval 1.474-1.750; rivaroxaban 1.88 IU/ml, P < 0.001, 95% confidence interval 1.745-2.020) (Fig. 5D) . Furthermore, in the presence of DOACs, PT increased with increasing concentrations of either LMWH or UFH ( Fig. 5B and E) . Particularly in the presence of apixaban and rivaroxaban and-to a lesser degree-dabigatran, prolongation extended even more with increasing concentrations of either LMWH or UFH, suggesting synergistic effects of DOACs and heparins. The aPTT curves reflect the additive effects of DOACs and heparins, whereby the coagulation times observed with UFH (versus LWMH) and dabigatran demonstrate the importance of thrombin inhibition. In the presence of dabigatran and rivaroxaban in particular, the upper measurement range is achieved even with small amounts of UFH (0.2-0.5 IU/ml, Fig.  5C ). In fact, Fig. 5 shows a similar effect of all DOACs regarding PT and aPTT in combination with spiked concentrations of UFH. The same concentrations of LMWH produced a weaker effect on the global parameters PT and aPTT.
Imitation of a bridging situation using samples containing DOAC (in vivo) and spiked with heparin (ex vivo)
A third subject of the study was the investigation of plasma samples from patients treated with the different DOACs, whereby the blood was taken immediately before (i.e. trough level) and at different times after the intake of the DOAC (dabigatran/apixaban: 0, 3, 6, 9h; rivaroxaban: 0, 3, 6, 12, or 15, or 18h). Plasma samples were spiked ex vivo with various concentrations of heparins. The pharmacokinetics of rivaroxaban (Fig.  6A) were measured using the aXa-assay, those of dabigatran (Fig. 6B ) using the dTT. In addition, the concentrations of all DOACs were analysed using liquid chromatography-mass spectrometry (LC/MS). As expected, additional LMWH (Fig. 6 ) and UFH (data not shown) had no effect on the quantification of DOACs by LC/MS. The pharmacokinetics of rivaroxaban determined with the aXa-assay showed, for a start, a similar profile independent of heparin concentration. However, with an increasing amount of spiked heparin, the assumed concentration level of rivaroxaban increased proportionally (Fig. 6A) . Similar results were obtained with samples from apixabantreated patients as well as with samples spiked with UFH instead of LMWH (data not shown). Compared with the DXI, dabigatran monitoring with dTT was influenced only slightly by LMWH (Fig. 6B) . Nonetheless, in the presence of supratherapeutic concentrations of UFH (>1.0 IU/ml), the increase of the dTT-based dabigatran concentrations was significant (data not shown). 
DISCUSSION
Since 2008, when dabigatran and rivaroxaban were approved for use after hip and knee surgery, more and more patients have been treated with DOACs. As a consequence, more questions have arisen from the daily use of these drugs. One of the major questions is the need for bridging therapy as commonly used for VKA. According to both the summary of product characteristics of the various DOACs and the latest version of the EHRA practical guide on the use of DOACs, no bridging is necessary for surgery or interventions with a higher bleeding risk, as the predictable waning of the anticoagulation effect allows properly timed shortterm cessation and reinitiating DOAC therapy before and after surgery [14] . These recommendations are underlined by subanalyses of the various Phase III studies showing an increase in major bleeding complications in patients receiving heparin bridging, especially in those patients undergoing major procedures [15] [16] [17] [18] . Notably, a large meta-analysis by Siegal et al. [19] , the data from the ORBIT-AF registry [9] as well as the prospective randomized clinical trials BRUISE CONTROL [20] and BRIDGE [21] indicate that increased bleeding under bridging therapy is most probably a general issue so that even the benefit of LMWH bridging in VKA-treated patients is currently under discussion to. Despite all these data, registry data have shown that bridging is still inappropriately used in DOAC patients, leading to a significantly higher periprocedural bleeding rate (without lower thromboembolic rate) [22] . This corresponds to a survey of 139 patients who were admitted to our hospital, a specialized clinic for thoracic and cardiovascular surgery, for cardiac surgery or intervention (from April 2014 until July 2015) and whose last DOAC intake was known. Twenty-five per cent of these patients received bridging therapy with LMWH. They were identified after recognition of a discrepancy between the aXa-assay calibrated with rivaroxaban or apixaban and mass spectrometry. Only 36% of these patients indicated this therapy on the presurgery questionnaire. These findings motivated our group to perform the described study and strengthened the importance of a close drug history.
The study investigated, for the first time, the influence of the three DOACs apixaban, rivaroxaban and dabigatran-as well as LMWH and UFH-on the currently most widely used monitoring assays for these anticoagulants (Fig. 4) . Additionally, the effects of various DOAC plus heparin combinations on these tests were investigated in order to evaluate the reliability of monitoring results in the case of any concomitant application of DOACs and heparins (Figs 5 and 6) .
Compared with heparins, the DXIs display steeper concentration-dependent curves in the aXa-assay. This could be due to the different modes of action of DXI and heparins, i.e. direct inhibition of FXa by binding to its active centre versus catalysing its inhibition with antithrombin [23] . Determination of DXI concentrations using heparin calibration results in apparently high concentrations (Fig. 4P , Q, U and V). However, it should be considered that DXIs inhibit coagulation exclusively by blocking FXa, whereas heparins interfere with coagulation by means of multiple mechanisms.
Measuring DXI/heparin combinations with routinely used assays proved fruitless (Fig. 5) , so that monitoring DXI in the case of concomitant use of heparin is possible only with LC/MS (Fig.  6 ) or after the degradation of heparin with heparinase.
Global haemostaseological parameters (PT, aPTT), which are of questionable value for DOAC monitoring [14] in general, turned out to be clearly inappropriate for patients with heparin and DOACs (Fig. 5B, C, E and F) . Furthermore, the values of activating clotting time (ACT), an assay based on kaolin clotting time, cannot be interpreted correctly in these patients [12] . This is especially important for interventions such as cardiothoracic surgery or cardiac catheter examination where ACT is still the assay of choice [7] .
Therefore, plasma levels of DOACs should be measured with the meanwhile available corresponding assays, i.e. routine aXaassays calibrated with the respective DXI and dTT in case of dabigatran, respectively. The obtained plasma levels of DOACs show a good correlation with the plasma concentrations measured with LC/MS, even at lower concentrations [13, 22] . This is not the case for VKA, which still impair coagulation even when the haemostatic global parameters PT (and aPTT) have been normalized.
LIMITATIONS
Despite of the available options to monitor DOACs, it has to be mentioned that so far no correlation has been found between plasma levels of DOACs and the risk of bleeding. To prove whether monitoring of DOACs can be useful to estimate the bleeding risk is therefore, an important topic that should be investigated in further clinical trials.
The presented work does certainly not help to solve this question, as it is a laboratory study mainly based on spiked plasma samples. But already the few samples from patients treated with DOACs indicate wide variations between individual plasma levels and pharmacokinetics, which additionally aggravate the interpretation of plasma levels.
PRACTICAL RECOMMENDATIONS
Nevertheless, the results of the study are of practical relevance for the peri-interventional management of those high-risk patients on DOACs such as those undergoing cardiothoracic surgery, for whom the guidelines from the European Society of Anaesthesiology suggest to consider bridging therapy with UFH or LMWH [24] . Our data suggest that in such cases, heparin therapy should be started only after measuring the residual concentration of the used DOAC with an appropriate assay and not before a concentration lower than 30 ng/ml has been achieved [25] .
CONCLUSION
As an overall conclusion, every hospital should establish a multimodal therapeutic plan for managing patients taking DOACs. This includes monitoring with the right assay at the right time, which then may help to draw useful conclusions.
Most important aspects regarding new DOAC for the practicing surgeon
• Routine monitoring of DOACs is not necessary due to their pharmacology completely differing from that of VKA.
• Monitoring of DOACs may be useful in certain situations such as surgery or interventions to exclude extreme plasma concentrations.
• The effects of the DOACs on routinely used coagulation and monitoring assays are known and suitable assays and calibrators for the monitoring of DOCAs are meanwhile available.
• There are considerable interindividual variations of the plasma levels of DOACs, but their clinical impact is still unknown.
• According to current recommendations, patients treated with DOACs should not receive bridging with heparins in case of surgery or interventions • However, intentionally or accidentally, DOAC patients often receive heparins so that blood samples drawn for monitoring may concomitantly contain both a DOAC and a heparin.
Most important new aspects or conclusions from this study
• Concomitant use of DXI and heparin affects the informative value of any monitoring.
• aPTT of plasma containing both a heparin and a DOAC is strongly prolonged.
• The presence of DXI leads to false-high heparin levels determined by aXa-assay.
• Heparins result in overestimated DOAC concentrations measured by aXa-assay or dTT, respectively.
• The pharmacokinetics of the DOACs may considerably vary between individual patients, which additionally complicates the interpretation of monitoring results under concomitant use of heparins
